Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Venous Thromboembolism | 3 | 2021 | 143 | 1.510 |
Why?
|
| Heart Arrest | 1 | 2022 | 162 | 0.690 |
Why?
|
| Mesentery | 1 | 2018 | 14 | 0.600 |
Why?
|
| Multidetector Computed Tomography | 1 | 2018 | 20 | 0.590 |
Why?
|
| Intestines | 1 | 2018 | 158 | 0.540 |
Why?
|
| Laparotomy | 2 | 2017 | 46 | 0.410 |
Why?
|
| Intra-Abdominal Hypertension | 1 | 2011 | 3 | 0.390 |
Why?
|
| Trauma Centers | 5 | 2024 | 119 | 0.390 |
Why?
|
| Intracranial Hypertension | 1 | 2011 | 10 | 0.390 |
Why?
|
| Multiple Trauma | 1 | 2011 | 27 | 0.380 |
Why?
|
| Decompression, Surgical | 1 | 2011 | 61 | 0.370 |
Why?
|
| Wounds and Injuries | 3 | 2024 | 244 | 0.350 |
Why?
|
| Brain Injuries | 1 | 2011 | 138 | 0.330 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2008 | 168 | 0.300 |
Why?
|
| Liver Neoplasms | 2 | 2008 | 278 | 0.280 |
Why?
|
| Benzodiazepines | 2 | 2024 | 101 | 0.270 |
Why?
|
| Anticoagulants | 2 | 2021 | 490 | 0.260 |
Why?
|
| Retrospective Studies | 6 | 2023 | 6206 | 0.240 |
Why?
|
| Risk Assessment | 2 | 2021 | 1957 | 0.230 |
Why?
|
| Cannabinoids | 1 | 2024 | 39 | 0.230 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 2023 | 4 | 0.220 |
Why?
|
| Accidental Falls | 1 | 2024 | 154 | 0.200 |
Why?
|
| Humans | 16 | 2024 | 61061 | 0.190 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2023 | 119 | 0.190 |
Why?
|
| Computed Tomography Angiography | 1 | 2022 | 118 | 0.190 |
Why?
|
| Ethanol | 1 | 2024 | 309 | 0.190 |
Why?
|
| Enoxaparin | 1 | 2021 | 16 | 0.180 |
Why?
|
| Pandemics | 2 | 2022 | 639 | 0.180 |
Why?
|
| Alcoholism | 1 | 2023 | 312 | 0.170 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 511 | 0.160 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2020 | 104 | 0.160 |
Why?
|
| Spleen | 1 | 2020 | 486 | 0.160 |
Why?
|
| Thoracic Injuries | 1 | 2018 | 49 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1606 | 0.140 |
Why?
|
| Risk Factors | 3 | 2021 | 5163 | 0.140 |
Why?
|
| Abdominal Injuries | 1 | 2017 | 30 | 0.130 |
Why?
|
| Adult | 6 | 2023 | 16253 | 0.130 |
Why?
|
| Adolescent | 2 | 2021 | 6051 | 0.130 |
Why?
|
| Wounds, Gunshot | 1 | 2017 | 53 | 0.130 |
Why?
|
| Liver | 1 | 2020 | 806 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 246 | 0.120 |
Why?
|
| New England | 3 | 2021 | 269 | 0.120 |
Why?
|
| Hematoma, Subdural, Intracranial | 1 | 2011 | 2 | 0.100 |
Why?
|
| Mannitol | 1 | 2011 | 14 | 0.100 |
Why?
|
| Glasgow Outcome Scale | 1 | 2011 | 17 | 0.100 |
Why?
|
| Intracranial Pressure | 1 | 2011 | 20 | 0.100 |
Why?
|
| APACHE | 1 | 2011 | 52 | 0.100 |
Why?
|
| Glasgow Coma Scale | 1 | 2011 | 44 | 0.100 |
Why?
|
| Brain Edema | 1 | 2011 | 31 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 724 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 109 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 367 | 0.090 |
Why?
|
| Accidents, Traffic | 1 | 2011 | 151 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 222 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 305 | 0.080 |
Why?
|
| Female | 7 | 2024 | 31771 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 2008 | 115 | 0.070 |
Why?
|
| Oncolytic Virotherapy | 1 | 2007 | 6 | 0.070 |
Why?
|
| Phenobarbital | 2 | 2023 | 13 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 173 | 0.070 |
Why?
|
| Herpesvirus 1, Human | 1 | 2007 | 78 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 206 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 5289 | 0.060 |
Why?
|
| Virus Replication | 1 | 2007 | 308 | 0.060 |
Why?
|
| Male | 5 | 2024 | 28501 | 0.060 |
Why?
|
| Toes | 1 | 2005 | 13 | 0.060 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2005 | 21 | 0.060 |
Why?
|
| Face | 1 | 2005 | 34 | 0.060 |
Why?
|
| Fingers | 1 | 2005 | 42 | 0.060 |
Why?
|
| Substance Abuse Detection | 1 | 2024 | 44 | 0.060 |
Why?
|
| Aged | 3 | 2024 | 13890 | 0.060 |
Why?
|
| Anticonvulsants | 1 | 2005 | 96 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 1541 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2007 | 854 | 0.050 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2005 | 166 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2005 | 232 | 0.050 |
Why?
|
| United States | 2 | 2024 | 7671 | 0.050 |
Why?
|
| Seizures | 1 | 2023 | 119 | 0.050 |
Why?
|
| Middle Aged | 3 | 2021 | 16897 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 38 | 0.050 |
Why?
|
| Factor Xa Inhibitors | 1 | 2021 | 35 | 0.050 |
Why?
|
| Prevalence | 1 | 2024 | 1322 | 0.040 |
Why?
|
| Injury Severity Score | 1 | 2020 | 103 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 424 | 0.030 |
Why?
|
| Neoplasms | 1 | 2007 | 1269 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3193 | 0.030 |
Why?
|
| Cetuximab | 1 | 2008 | 8 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 18 | 0.020 |
Why?
|
| Vimentin | 1 | 2008 | 18 | 0.020 |
Why?
|
| Quinazolines | 1 | 2008 | 22 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2008 | 20 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2008 | 30 | 0.020 |
Why?
|
| Cadherins | 1 | 2008 | 68 | 0.020 |
Why?
|
| Mesoderm | 1 | 2008 | 84 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2008 | 71 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 360 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 188 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 4436 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 881 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 237 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2008 | 381 | 0.020 |
Why?
|
| Facies | 1 | 2005 | 7 | 0.020 |
Why?
|
| Carbamazepine | 1 | 2005 | 12 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2005 | 26 | 0.010 |
Why?
|
| Phenytoin | 1 | 2005 | 18 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 1392 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 862 | 0.010 |
Why?
|
| Animals | 2 | 2008 | 19880 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 2406 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 2379 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2007 | 5355 | 0.010 |
Why?
|
| Child | 1 | 2005 | 4388 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 10393 | 0.010 |
Why?
|